Affiliation:
1. Obstetrics and Gynecology Unit 1, Sant' Anna Hospital, Department of Surgical Sciences University of Turin Turin Italy
2. Obstetrics and Gynecology Unit 2, Sant' Anna Hospital, Department of Surgical Sciences University of Turin Turin Italy
3. Pathology Unit, Department of Medical Sciences University of Turin Turin Italy
Abstract
AbstractHuman papillomavirus (HPV) encompasses a group of viruses that infect the skin and mucous membranes. In the presence of certain factors, persistent infection with high‐risk HPVs can trigger a process of neoplastic transformation. Imiquimod is a topical agent that acts as a Toll‐like receptor 7/8 agonist, stimulating the innate and adaptive immune system to exert antitumor and antiviral effects. It has been approved for the treatment of various skin conditions, however, its efficacy and safety in the management of HPV‐related‐neoplasms of the lower genital tract, such as vulvar, vaginal, and cervical neoplasia, are still under investigation. This review summarizes the current evidence on the use of imiquimod for the treatment of HPV‐induced lesions of the female lower genital tract, focusing on its indications, mechanisms of action, outcomes, and predictors of response.
Subject
Infectious Diseases,Virology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献